Morris & Dickson (M&D), an independent wholesale and specialty pharma distributor, has officially acquired Prodigy Health, a fellow specialty pharmaceutical distribution and services company.¹ An original letter of intent for the acquisition was signed in December 2025.²

Prodigy Health will now begin to operate as ProdigyMD.

The deal reportedly strengthens Morris & Dickson’s specialty portfolio and broadens access to plasma-derived therapies, while maintaining continuity, regulatory compliance, and uninterrupted service for healthcare providers across the US.

As a result, M&D also expands its ability to better serve hospitals, specialty pharmacies, clinics, infusion centers, and alternate sites of care as demand for specialty and plasma therapies continues to rise. For manufacturers, the combined organization offers a larger independent distribution network with greater reach, specialty expertise, and a compliance-driven operating model.

“This transaction reflects our long-term commitment to specialty distribution and alternative sites of care,” said Jody Hatcher, CEO of Morris & Dickson. “Our focus is on expanding access to critical therapies while preserving continuity for customers and operating with regulatory integrity that is consistent with our independent, customer-first values.”

What strategic benefits does the Prodigy Health acquisition deliver?

Emphasizing the strategic importance of the acquisition, Layne Martin, M&D’s head of specialty, highlighted how the move strengthens the company’s specialty capabilities and customer support model.

“This is a meaningful step forward in our specialty strategy,” he said. “By bringing Prodigy Health’s purpose-built plasma and specialty expertise into the Morris & Dickson family, we are strengthening our ability to support complex therapies while maintaining the service and compliance our customers expect. Our immediate focus is disciplined execution and personalized customer support.”

How will the phased integration impact customers and manufacturers?

A company release¹ shares that Morris & Dickson is expected to begin a “phased integration process” powered by industry practices that abide by regulatory requirements. The goal is for customers and manufacturers to be able to benefit from the advantages of both parties without losing out on any advantages.

This can be outlined by two advantages:

1. Customers will continue to experience ordering, fulfillment, and support while Morris & Dickson incorporates Prodigy Health’s specialty tools.
2. Manufacturers will be granted additional access to a distribution platform that utilizes its specialty focus to support complex therapies.

How does Morris & Dickson’s workflow support compliance and supply chain reliability?

Earlier this year, Hatcher sat down with Pharma Commerce to discuss his day-to-day workflow at the company, and how it supports the efficiency and reliability of its operations.

“Our workflow and processes are built around complementing those of our customers and our trade partners,” Hatche explained. “For Morrison & Dixon, day-to-day workflow is a balance of knowledge, automation, and ultimately, the personal service that we provide to our customers. The funny thing about what we do is that our day largely starts when others are likely asleep. I say that in earnest, but it does begin upstream with our trade partners, including our commercial team.

“We've got over 400 manufacturing partners that we work with, and we really work closely with them to monitor the drug pipelines, manage the market, monitor pricing—all of those things that are critical to making sure that we're paying attention to the upstream elements of the marketplace, and then that ultimately translates into the physical receipt of the product from our trade partners into our distribution center. We bring it into the facility. It's got to be received and scanned such that we're receiving EPCIS data all per the DSCSA requirements, and then ultimately, what we rely on is a dedicated and committed team of folks who are receiving and then packing and shipping, while maintaining the integrity of the product.”

References

1. Morris & Dickson Completes Transaction to Acquire Prodigy Health. Morris & Dickson. January 26, 2026. Accessed January 28, 2026. https://www.morrisdickson.com/2026/01/26/morris-dickson-completes-transaction-to-acquire-prodigy-health/

2. Morris & Dickson LLC Signs Letter of Intent to Acquire Prodigy Health. Morris & Dickson. December 8, 2025. Accessed January 28, 2026. https://www.morrisdickson.com/2025/12/08/morris-dickson-llc-signs-letter-of-intent-to-acquire-prodigy-health/